UNSPSC 51241144: Aflibercept

Aflibercept injection is a prescription medicine administered by injection into the eye. It is a vascular endothelial growth factor (VEGF) inhibitor. https://www.eylea.us/

UNSPSC 51241144 Aflibercept, a Commodity code, shows minimal recent state and local procurement activity aligned with its nominal pharmaceutical scope. The two recent opportunities tagged to this code reflect chemical procurement unrelated to aflibercept—a recombinant fusion protein used in ophthalmology and oncology. Texas A&M University Division of Finance Procurement Services issued ITB TAMU-ITB-26-5055 for precipitant solutions with a response deadline of July 15, 2026, and Pasco County, Florida solicited an as-needed supply contract for large copper sulfate crystals and liquid copper sulfate with a response deadline of June 26, 2026. Neither solicitation concerns aflibercept or biopharmaceutical products. State and local procurement offices do purchase specialty pharmaceuticals—including biologics and injectables for public health programs, medical facilities, and institutional research—but this code's tagging suggests a taxonomy misalignment rather than active state and local demand for aflibercept specifically.

Recent activity appears concentrated in Florida and Texas, though the sample is too small to establish meaningful geographic patterns. The issuing bodies are an academic research institution and a county government, neither of which typically appears as a high-volume aflibercept buyer in state and local procurement. Without evidence of recent solicitations for the product itself, practitioners should monitor this code for corrected opportunities or wait for clearer demand signals before allocating pursuit resources. If your firm supplies aflibercept to state health systems, Medicaid programs, or institutional pharmacy networks, search those agencies' procurement portals directly rather than rely on this code's current tagging.